Source-grounded facts extracted from Allarity Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Allarity Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.
“On March 31, 2026, Allarity Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended December 31, 2025.”
Allarity Therapeutics, Inc. entered into Note Purchase Agreement with Streeterville Capital, LLC valued at $20,930,000 aggregate principal (A-1 Note $10,930,000, B Note $10,000,000) (effective 2026-03-02).
“On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).”
Allarity Therapeutics, Inc. incurred loan of $10,930,000 (A-1 Note) and $10,000,000 (B Note) with Streeterville Capital, LLC at 9.00% per annum and 5.00% per annum maturing 18 months following the date of issuance.
“On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as defined below), the “ A Notes ”) and (ii) a secured promissory note in the original principal amount of $10,000,000 (the “ B Note ,” and together with the A Notes, the “ Notes ”; each individually, a “ Note” ).”
Allarity Therapeutics, Inc. entered into Common Stock Purchase Agreement with Tumim Stone Capital LLC (effective 2026-01-28).
“On January 28, 2026, Allarity Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with Tumim Stone Capital LLC, a Delaware limited liability company (the “ Investor ”).”
Allarity Therapeutics, Inc. issued 255,103 shares of common stock to a certain accredited investor for $0.98 per Share.
“At the Additional Closing, the Company agreed to issue and sell 255,103 shares (the “Additional Shares”) of the Company’s Common Stock, for $0.98 per Share”
Allarity Therapeutics, Inc. issued warrant to a certain accredited investor for $0.0001 exercise price per Pre-Funded Warrant; purchase price $1.5999 per Pre-Funded Warrant.
“the Company has agreed to issue and sell 1,562,500 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for $1.60 per Share, and/or pre-funded warrants in (the “Pre-Funded Warrants) to purchase one share of Common Stock per Pre-Funded Warrant, at an offering price of $1.5999 per Pre-Funded Warrant (the “Purchase Price”), for gross proceeds to the Company of approximately $2.5 million, before deducting fees and expenses.”
Allarity Therapeutics, Inc. issued 1,562,500 shares of common stock to a certain accredited investor for $1.60 per Share, for gross proceeds of approximately $2.5 million.
“the Initial Closing, the Company has agreed to issue and sell 1,562,500 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for $1.60 per Share, and/or pre-funded warrants in (the “Pre-Funded Warrants) to purchase one share of Common Stock per Pre-Funded Warrant, at an offering price of $1.5999 per Pre-Funded”
Jesper Høiland was appointed as director at Allarity Therapeutics, Inc..
“On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025.”
Joseph W. Vazzano resigned as director at Allarity Therapeutics, Inc..
“On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025.”
Jeremy R. Graff was appointed as President and Chief Development Officer at Allarity Therapeutics, Inc..
“On October 3, 2024, Allarity Therapeutics, Inc. (the “Company”) announced the appointment of Jeremy R. Graff, as the President and Chief Development Officer of the Company effective as of September 30, 2024.”
Alexander Epshinsky was appointed as Chief Financial Officer at Allarity Therapeutics, Inc..
“On September 12, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Alexander Epshinsky as the Chief Financial Officer of the Company as of September 12, 2024, succeeding Ms. Brown.”
Joan Y. Brown resigned as Chief Financial Officer at Allarity Therapeutics, Inc..
“On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.”
Allarity Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income -$3.8 million.
“Net loss was $3.8 million for the quarter ended March 31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.”
Allarity Therapeutics, Inc.: Filed Fifth Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2024-04-09).
“On April 4, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”) filed a Fifth Certificate of Amendment to Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 9:30 a.m. (Eastern Time) on April 9, 2024”
Allarity Therapeutics, Inc. shareholders approved Approve adjournment of special meeting to solicit additional proxies in favor of Reverse Stock Split Proposal.
“Proposal 3 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 4,598,095 1,130,018 4,143 -”
Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect reverse stock split at ratio between 1:5 and 1:20.
“Proposal 2 : To approve an amendment to the Allarity Therapeutics, Inc. Certificate of Incorporation, as amended (the “Charter Amendment”), in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-5 and 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 4,619,400 1,095,954 16,902 -”
Allarity Therapeutics, Inc. shareholders approved Approve amendment to 2021 Equity Incentive Plan to increase authorized shares by 1,000,000.
“Proposal 1 : To approve an amendment to the Allarity Therapeutics, Inc. 2021 Equity Incentive Plan, a copy of such amended and restated plan is included as Appendix A to the Proxy Statement (the “2021 Plan”), to increase the aggregate number of shares of Common Stock authorized for issuance by 1,000,000 shares (the “Amendment to the 2021 Plan Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 3,898,165 294,784 1,917 1,537,390”
Allarity Therapeutics, Inc. entered into At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $947,000 (effective 2024-03-19).
“On March 19, 2024, Allarity Therapeutics, Inc. (the “ Company ”), entered into an At-The-Market Issuance Sales Agreement (the “ Agreement ”) with Ascendiant Capital Markets, LLC (the “ Agent ”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares”
Allarity Therapeutics, Inc.: Filing of Seventh Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to reduce conversion price from $0.405 to $0.3501 (effective 2024-03-14).
“On March 14, 2024, we filed the Seventh Amendment to change the “Conversion Price” from $0.405 to $0.3501.”
Allarity Therapeutics, Inc. incurred convertible notes of $660,000 with 3i, LP at 8% per annum maturing March 14, 2025.
“On March 14, 2024 (the “Subsequent Closing”), we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $660,000 (the “Principal Amount”) due on March 14, 2025 (the “Note,””
Allarity Therapeutics, Inc. entered into Securities Purchase Agreement (Note) with 3i, LP valued at $660,000 senior convertible promissory note, 8% interest, conversion price $0.3501 (effective 2024-03-14).
“Item 1.01 Entry into a Material Definitive Agreement. Subsequent Closing As previously disclosed, on January 18, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement, as amended by the First Amendment to Securities Purchase Agreement, dated as of January 25, 2024 (as so amended, the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser” and together with us, the “Parties”). On March 14, 2024 (the “Subsequent Closing”), we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $660,000 (the “Principal Amount”) due on March 14, 2025 (the “Note,” and together with the Notes issued on January 18, 2024 and February 13, 2024, and the Purchase Agreement, the “Transaction Documents”) for an aggregate purchase price of $600,000, representing an approximately 10% original issue discount (the “Transaction”).”
Allarity Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $11.9 million.
“Net loss was $11.9 million for 2023, compared to $16.1 million for 2022.”
Marie Foegh was terminated as Chief Medical Officer at Allarity Therapeutics, Inc..
“On February 28, 2024, Allarity Therapeutics, Inc. (the “Company”) terminated the employment of Marie Foegh, M.D., the Company’s Chief Medical Officer. Ms. Foegh’s last day of employment was February 29, 2024.”
Allarity Therapeutics, Inc. amended Amendment to Senior Convertible Notes with 3i, LP (effective 2024-02-27).
“On February 27, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership, (the “Holder” and together with us, the “Parties”) entered into an Amendment to Senior Convertible Notes (the “Amendment”) to two senior convertible notes dated as of January 18, 2024 and February 13, 2024”
Allarity Therapeutics, Inc.: Amended Series A Preferred Stock conversion price from $0.4476 to $0.405 via Sixth Certificate of Amendment (effective 2024-02-13).
“On February 13, 2024, we filed the Sixth Amendment to change the “Conversion Price” from $0.4476 to $0.405.”
Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing 2025-02-13.
“we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on February 13, 2025”
Allarity Therapeutics, Inc. entered into Limited Waiver Agreement and Second Convertible Promissory Note with 3i, LP valued at $440,000 principal, $400,000 purchase price, 8% interest, convertible at $0.405/share (effective 2024-02-13).
“On February 13, 2024 (the “Second Closing”), the Parties entered into a Limited Waiver Agreement (the “Waiver Agreement”) and agreed that the Second Closing can be consummated prior to the 30 th calendar day following January 18, 2024.”
Allarity Therapeutics, Inc. terminated Agreement with Novartis Pharma AG (effective 2024-01-26).
“On January 26, 2024, we received written notice from Novartis indicating their decision to terminate the Agreement based on material breach for lack of financial payment.”
James G. Cullem resigned as Director at Allarity Therapeutics, Inc..
“On January 27, 2024, the Chairman of our Board of Directors (the “Board”), received email correspondence from Mr. James G. Cullem tendering his resignation (the “Resignation Email”) as a member of our Board.”
Allarity Therapeutics, Inc. amended Amendment with 3i, LP (effective 2024-01-25).
“On January 25, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership (the “Purchaser”), executed an amendment (the “Amendment”) to that certain Securities Purchase Agreement dated as of January 18, 2024 (the “Original Agreement”).”
Allarity Therapeutics, Inc. incurred convertible notes of $440,000 with 3i, LP at 8% per annum maturing January 18, 2025.
“we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000 (the “Principal Amount”) due on January 18, 2025”
Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with 3i, LP valued at $440,000 (effective 2024-01-18).
“On January 18, 2024 (the “First Closing Date”), Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with 3i, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which we issued and sold to the Purchaser a senior convertible promissory note in an aggregate principal amount of $440,000”
Thomas Jensen was appointed as Chief Executive Officer at Allarity Therapeutics, Inc..
“On December 8, 2023, Mr. Thomas Jensen, age 45, was appointed by the Company’s Board of Directors as Chief Executive Officer.”
James Cullem was terminated as Chief Executive Officer at Allarity Therapeutics, Inc..
“On December 8, 2023, Mr. James Cullem was terminated as Chief Executive Officer of Allarity Therapeutics, Inc. (the “Company”) and all other positions with the Company and its subsidiaries.”
Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Form 10-Q”), did not satisfy the continued listing requirement under Listing Rule 5550(b)(1) for The Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on the Form 10-Q, the Company’s stockholders’ equity as of September 30, 2023 was ($3,379,000). Pursuant to the Staff letter , the Company is not eligible for a 180-calendar day”
Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“October 27, 2023, we received a notification from Staff that it has determined that the bid price of our Common Stock has closed at less than $1 per share over the previous 30 consecutive business days, and did not comply with Listing Rule 5550(a)(2). As a result, our Common Stock will be delisted from The Nasdaq Capital Market. We have appealed such determination by requesting a hearing. The hearing has been scheduled for February 1, 2024 before a Nasdaq Hearing Panel (the “Panel Hearing”). On November 16, 2023, we received a letter from Staff notifying us that the Company’s stockholders’ equ”
Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).
“October 27, 2023, we received notification from the Nasdaq Listing Qualifications staff that it has determined that the bid price of our Common Stock has closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, does not comply with Listing Rule 5550(a)(2) (the “Rule”). Further, the staff also noted that we effected an 1:35 reverse stock split on March 24, 2023, and an 1:40 reverse stock split on June 28, 2023. Because we effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, we wil”
Allarity Therapeutics, Inc.: Fourth Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock filed to reduce the conversion price from $4.50 to $1.00 (effective 2023-09-22).
“On September 22, 2023 the Company filed the Fourth Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock”
Robert Oliver resigned as director at Allarity Therapeutics, Inc..
“On August 7, 2023, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) received the resignation of Mr. Robert Oliver as director of the Company, including his position on each Board committee on which he was appointed to, effective immediately.”
Robert Oliver was appointed as Director at Allarity Therapeutics, Inc..
“Class III Director: Mr. Robert Oliver, whose term will expire at the Company’s 2025 annual meeting of stockholders or until his respective successors are duly elected and qualified.”
Laura Benjamin was appointed as Director at Allarity Therapeutics, Inc..
“Class II Director: Dr. Laura Benjamin, whose term will expire at the Company’s 2024 annual meeting of stockholders or until her respective successors are duly elected and qualified.”
Joe Vazzano was appointed as Director at Allarity Therapeutics, Inc..
“Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.”
David Roth resigned as Director at Allarity Therapeutics, Inc..
“On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.”
Allarity Therapeutics, Inc.: Reduced conversion price of Series A Convertible Preferred Stock from $8.00 to $4.50 via Third Certificate of Amendment to Amended and Restated Certificate of Designations (effective 2023-07-11).
“On July 11, 2023, we filed a Third Amendment to change the “Conversion Price” from $8.00 to $4.50.”
Allarity Therapeutics, Inc. amended Amended and Restated Common Stock Purchase Warrant with the investors who acquired securities in the April Offering (effective 2023-07-10).
“Concurrent with the close of the Offering, the Company entered into an Amended and Restated Common Stock Purchase Warrant to memorialize the repricing and the extension of termination date (“Amended and Restated Warrant”).”
Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-07-05).
“Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).”
Allarity Therapeutics, Inc. entered into Purchase Agreement with the Purchasers valued at approximately $11 million (effective 2023-07-05).
“On July 5, 2023, Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) agreed to sell in a public offering an aggregate of 357,223 shares of Common Stock of the Company (the “Shares”), pre-funded warrants to purchase up to 2,087,222 shares of Common Stock (the “Pre-Funded Warrants”), and common warrants to purchase up to 2,444,445 shares of Common Stock (the “Common Warrants” together with the Shares, the Pre-Funded Warrants and Common Stock issuable upon exercise of the Common Warrants and the Pre-Funded Warrants, collectively, the “Securities”), at an effective combined purchase price of $4.50 per share and related Common Warrant (the “Purchase Price”), for aggregate gross proceeds of approximately $11 million, before deducting placement agent fees and offering expenses payable by the Company (the “Offering”). The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto (each, a “Pu”
Allarity Therapeutics, Inc. incurred loan of $350,000 with 3i LP at 5% per annum maturing July 31, 2023.
“Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000 to be issued at closing (the “Note”). The closing for the Note occurred on June 30, 2023 and the purchase price for the Note was paid in cash (“Closing”). The Note matures on July 31, 2023, carries an interest rate of at 5% per annum”
Allarity Therapeutics, Inc. entered into Secured Note Purchase Agreement with 3i LP valued at $350,000 (effective 2023-06-29).
“On June 29, 2023, Allarity Therapeutics, Inc. (the “Company”) entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP, the sole holder of the Company’s outstanding shares of Series A Preferred Stock. Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000”
Allarity Therapeutics, Inc.: Filed Fourth Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock (effective 2023-06-28).
“On June 28, 2023, upon receipt of the required stockholder approval, Allarity Therapeutics, Inc. (the “Company”) filed a Fourth Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on June 28, 2023 (the “Reverse Stock Split”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.